Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 742

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 742
---
 | ​                        | ​ | -28,032 | ​ | ​ |
| Other comprehensive income                                                | ​      | ​ | ​            | ​ |         — | ​ | ​      | ​ | ​ | ​ | — | ​ | ​ | ​ | ​                        | ​ |       — | ​ | ​ | ​ | ​                  | ​ |        — | ​ | ​ | ​ | ​                                 | ​ |    291 | ​ | ​ | ​ | ​                        | ​ |     291 | ​ | ​ |
| Balance at September 30, 2023                                             | ​      | ​ | ​            | ​ | 4,539,319 | ​ | ​      | ​ | ​ | $ | 5 | ​ | ​ | ​ | ​                        | $ | 738,484 | ​ | ​ | ​ | ​                  | $ | -652,408 | ​ | ​ | ​ | ​                                 | $ |   -439 | ​ | ​ | ​ | ​                        | $ |  85,642 | ​ | ​ |

See Notes to Condensed Consolidated Financial Statements. F-5

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(unaudited)

| ​                                                                                                                          
 ​                                                                                                                          
 Operating activities                                                                                                       | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months Ended, 
 September 30,2024  
 ​                  | ​ |       ​ | ​ | ​ 
 ​ | ​ 
 ​ | September 30,2023 
 ​                 | ​ |       ​ | ​ | ​ 
 ​ 
 ​ |
|:---------------------------------------------------------------------------------------------------------------------------|:--|:--|:-------------------|:--|--------:|:--|:--|:--|:------------------|:--|--------:|:--|:--|
| Net loss                                                                                                                   | ​ | ​ | ​                  | $ | -63,188 | ​ | ​ | ​ | ​                 | $ | -86,176 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities:                                                | ​ | ​ | ​                  | ​ |       ​ | ​ | ​ | ​ | ​                 | ​ |       ​ | ​ | ​ |
| Stock-based compensation expense                                                                                           | ​ | ​ | ​                  | ​ |   6,575 | ​ |